Search Results

Jasper Therapeutics, Inc. today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.

Intensity Therapeutics, Inc. today announced that it has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.

Intensity Therapeutics, Inc. today announced that safety, tolerability, efficacy and immune activation data from the company’s Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.

Oncocyte’s VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine.

Ascendis Pharma A/S announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.

Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the BMO Virtual BioPharma Spotlight Series: Oncology Day on Wednesday, November 8, 2023, at 1:00 p.m. ET.